Veridex, LLC provides in vitro diagnostic oncology products to physicians. The company provides CellSearch CTC Test, an in vitro diagnostic blood test to capture and count circulating tumor cells to determine the prognosis of patients with metastatic breast, colorectal, or prostate cancer. It also provides tools and services that are used for the selection, identification, and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers aiding scientists in the search for new targeted therapies. The company was founded in 2004 and is based in Raritan, New Jersey. Veridex, LLC operates as a subsidiary of Johnson & Johnson
